AR033452A1 - Antagonistas de ccr5 utiles para el tratamiento del sida - Google Patents

Antagonistas de ccr5 utiles para el tratamiento del sida

Info

Publication number
AR033452A1
AR033452A1 ARP020101142A ARP020101142A AR033452A1 AR 033452 A1 AR033452 A1 AR 033452A1 AR P020101142 A ARP020101142 A AR P020101142A AR P020101142 A ARP020101142 A AR P020101142A AR 033452 A1 AR033452 A1 AR 033452A1
Authority
AR
Argentina
Prior art keywords
alkyl
aryl
fluoroalkyl
cycloalkyl
heteroaryl
Prior art date
Application number
ARP020101142A
Other languages
English (en)
Spanish (es)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR033452A1 publication Critical patent/AR033452A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
ARP020101142A 2001-03-29 2002-03-27 Antagonistas de ccr5 utiles para el tratamiento del sida AR033452A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27993801P 2001-03-29 2001-03-29

Publications (1)

Publication Number Publication Date
AR033452A1 true AR033452A1 (es) 2003-12-17

Family

ID=23070981

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101142A AR033452A1 (es) 2001-03-29 2002-03-27 Antagonistas de ccr5 utiles para el tratamiento del sida

Country Status (29)

Country Link
US (5) US6720325B2 (enExample)
EP (2) EP1373256B1 (enExample)
JP (2) JP4248251B2 (enExample)
KR (1) KR100613528B1 (enExample)
CN (1) CN100519554C (enExample)
AR (1) AR033452A1 (enExample)
AT (2) ATE466009T1 (enExample)
AU (1) AU2002255947B8 (enExample)
BR (1) BR0208398A (enExample)
CA (1) CA2442227C (enExample)
CZ (1) CZ20032636A3 (enExample)
DE (2) DE60204951T2 (enExample)
DK (1) DK1373256T3 (enExample)
ES (2) ES2342942T3 (enExample)
HU (1) HUP0400349A3 (enExample)
IL (1) IL157551A0 (enExample)
MX (1) MXPA03008853A (enExample)
MY (1) MY128609A (enExample)
NO (1) NO326349B1 (enExample)
NZ (1) NZ527768A (enExample)
PE (1) PE20020996A1 (enExample)
PL (1) PL364560A1 (enExample)
PT (1) PT1373256E (enExample)
RU (1) RU2316553C2 (enExample)
SI (1) SI1373256T1 (enExample)
SK (1) SK287521B6 (enExample)
TW (1) TWI237638B (enExample)
WO (1) WO2002079194A1 (enExample)
ZA (1) ZA200307474B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2342942T3 (es) * 2001-03-29 2010-07-19 Schering Corporation Antagonistas de ccr5 utiles para el tratamiento del sida.
DK1404667T3 (da) 2001-07-02 2006-07-10 Astrazeneca Ab Piperidinderivater, der er anvendelige som modulatorer af chemokinreceptoraktivitet
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
US7132539B2 (en) 2002-10-23 2006-11-07 The Procter & Gamble Company Melanocortin receptor ligands
DE60324014D1 (de) * 2002-12-13 2008-11-20 Smithkline Beecham Corp Heterocyclische verbindungen alsccr5-antagonisten
PE20040769A1 (es) * 2002-12-18 2004-11-06 Schering Corp Derivados de piperidina utiles como antagonisas ccr5
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
CA2544377A1 (en) * 2003-11-03 2005-05-12 Schering Corporation Bipiperidinyl derivatives useful as inhibitors of chemokine receptors
ES2324224T3 (es) * 2004-02-05 2009-08-03 Schering Corporation Derivados de piperidina que se pueden utilizar como antagonistas ccr3.
SE0400925D0 (sv) * 2004-04-06 2004-04-06 Astrazeneca Ab Chemical compounds
US7678798B2 (en) 2004-04-13 2010-03-16 Incyte Corporation Piperazinylpiperidine derivatives as chemokine receptor antagonists
PE20060598A1 (es) * 2004-09-13 2006-08-21 Ono Pharmaceutical Co Derivado heterociclo conteniendo nitrogeno como antagonista de quimiocina ccr5
US7635698B2 (en) 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
WO2006071875A1 (en) 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
JP2008526862A (ja) * 2005-01-06 2008-07-24 シェーリング コーポレイション ピペラジン化合物の薬学的な塩の調製
JP2008526863A (ja) * 2005-01-06 2008-07-24 シェーリング コーポレイション Ｃｃ５ｒ受容体アンタゴニストの合成
AU2006216731A1 (en) * 2005-02-23 2006-08-31 Schering Corporation Piperidinyl piperazine derivatives useful as inhibitors of chemokine receptors
JP4822367B2 (ja) * 2005-02-23 2011-11-24 シェーリング コーポレイション ケモカイン受容体のインヒビターとして有用なピペリジニルピペリジン誘導体
KR20080037655A (ko) 2005-07-21 2008-04-30 아스트라제네카 아베 신규 피페리딘 유도체
US7462485B2 (en) * 2005-10-07 2008-12-09 Glaser Lawrence F Modified erythrocytes and uses thereof
TW200745087A (en) * 2006-02-24 2007-12-16 Schering Corp CCR5 antagonists useful for treating HIV
US20080108586A1 (en) * 2006-09-06 2008-05-08 Incyte Corporation Combination therapy for human immunodeficiency virus infection
JP2010513521A (ja) * 2006-12-22 2010-04-30 シェーリング コーポレイション ４−置換１−シクロプロパン−スルホニル−ピペリジニル化合物を利用する、ｃｃｒ−５レセプターアンタゴニストを調製するためのプロセス
WO2009111218A2 (en) * 2008-02-29 2009-09-11 Schering Corporation Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5368854A (en) 1992-08-20 1994-11-29 Schering Corporation Use of IL-10 to treat inflammatory bowel disease
AU6135294A (en) 1993-02-12 1994-08-29 Merck & Co., Inc. Piperazine derivatives as hiv protease inhibitors
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
ES2182993T3 (es) 1995-06-07 2003-03-16 Kimberly Clark Co Inhibicion de exoproteinas en articulos absorbentes.
NZ321575A (en) 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
US5952349A (en) 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
US5977138A (en) 1996-08-15 1999-11-02 Schering Corporation Ether muscarinic antagonists
AU8576098A (en) 1997-07-25 1999-02-16 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
US6066636A (en) 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists
EP1013276A1 (en) * 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
EP1175402B1 (en) 1999-05-04 2005-07-20 Schering Corporation Piperidine derivatives useful as ccr5 antagonists
CZ20013940A3 (cs) * 1999-05-04 2002-04-17 Schering Corporation Piperazinové deriváty uľitečné jako CCR5 antagonisté
ES2342942T3 (es) * 2001-03-29 2010-07-19 Schering Corporation Antagonistas de ccr5 utiles para el tratamiento del sida.

Also Published As

Publication number Publication date
RU2316553C2 (ru) 2008-02-10
IL157551A0 (en) 2004-03-28
HUP0400349A2 (hu) 2004-12-28
RU2003131879A (ru) 2005-05-10
NO326349B1 (no) 2008-11-17
NO20034311L (no) 2003-11-26
SK287521B6 (sk) 2010-12-07
US6900211B2 (en) 2005-05-31
ZA200307474B (en) 2004-12-24
US20050143390A1 (en) 2005-06-30
CZ20032636A3 (cs) 2003-12-17
NZ527768A (en) 2005-03-24
SI1373256T1 (sl) 2005-12-31
HK1057363A1 (en) 2004-04-02
MY128609A (en) 2007-02-28
CA2442227A1 (en) 2002-10-10
US6720325B2 (en) 2004-04-13
AU2002255947B2 (en) 2005-10-27
ES2342942T3 (es) 2010-07-19
SK11962003A3 (sk) 2004-03-02
HK1083505A1 (en) 2006-07-07
PT1373256E (pt) 2005-11-30
EP1591444A1 (en) 2005-11-02
US7008946B2 (en) 2006-03-07
ATE466009T1 (de) 2010-05-15
DE60236218D1 (de) 2010-06-10
US7060701B2 (en) 2006-06-13
WO2002079194A1 (en) 2002-10-10
BR0208398A (pt) 2004-06-15
PL364560A1 (en) 2004-12-13
DE60204951D1 (de) 2005-08-11
JP4248251B2 (ja) 2009-04-02
MXPA03008853A (es) 2003-12-04
US20050059666A1 (en) 2005-03-17
US20060063771A1 (en) 2006-03-23
JP2004525157A (ja) 2004-08-19
AU2002255947B8 (en) 2005-11-17
EP1591444B1 (en) 2010-04-28
US20030008877A1 (en) 2003-01-09
CN100519554C (zh) 2009-07-29
HUP0400349A3 (en) 2010-03-29
PE20020996A1 (es) 2002-11-01
CN1547580A (zh) 2004-11-17
NO20034311D0 (no) 2003-09-26
US7098213B2 (en) 2006-08-29
JP2008074862A (ja) 2008-04-03
ES2242856T3 (es) 2005-11-16
ATE299139T1 (de) 2005-07-15
TWI237638B (en) 2005-08-11
KR20030083014A (ko) 2003-10-23
CA2442227C (en) 2008-10-28
DE60204951T2 (de) 2006-05-11
EP1373256B1 (en) 2005-07-06
DK1373256T3 (da) 2005-10-10
EP1373256A1 (en) 2004-01-02
KR100613528B1 (ko) 2006-08-16
US20040157854A1 (en) 2004-08-12

Similar Documents

Publication Publication Date Title
AR033452A1 (es) Antagonistas de ccr5 utiles para el tratamiento del sida
AR057873A2 (es) Compuestos derivados de piperizina utiles como antagonistas ccr5, composiciones farmaceuticas que los comprenden, y el uso de los mismos para la preparacion de medicamentos
CO5170522A1 (es) Derivados de piperidina utiles como antagonsitas de ccr5
SE0302487D0 (sv) Novel compounds
AR026410A1 (es) ''2-aril-3-(heteroaril)-imidazo[1,2-a]pirimidinas sustituidas, y las composiciones y metodos farmaceuticos relacionados
EA200500601A1 (ru) Выбранные cgrp-антагонисты, способ их получения, а также их применение в качестве лекарственных средств
AR045595A1 (es) Composiciones utiles como inhibidores de proteinas quinasas
AR012593A1 (es) Pirrolopiridinas sustituidas, composicion farmaceutica que las contiene, procedimiento para su preparacion y el uso de las mismas en la manufacturade un medicamento
ECSP045209A (es) Nuevos esteres de ácidos fluoreno - carboxilicos, procedimientos para su preparación asi como su utilización en calidad de medicamentos
CY1105198T1 (el) Παραγωγα πιπepιδινης χρησιμα σαν ανταγωνιστες ccr5 για τη θepαπεια ιου ανθρωπινης ανοσοανεπαρκειας (hiv)
AR016422A1 (es) Compuestos de esteres ciclicos de piperidinilaminometil trifluorometilo como antagonista de la sustancia p; composiciones farmaceuticas y procedimientos detratamiento.
ES2141922T3 (es) Tiazepinonas de benzotiofeno, benzofurano e indol, oxazepinonas y diazepinonas usadas como inhibidores de la adherencia celular y del vih.
DE60239193D1 (de) Neues amlodipincamsylat und verfahren zu dessen herstellung
SE0200919D0 (sv) Chemical compounds
AR001931A1 (es) Compuesto de 7-acilamino-3-iminometil (sustituido)cefalosporinas un proceso para su producción intermediarios en su producción una composición farmacéutica que contiene tales compuestos su utilizacióncomo compuestos farmacéuticos y un método para tratar enfermedades microbianas mediante administración de tales compuestos
ATE301990T1 (de) Pharmazeutische desmopressin-zubereitung als feste darreichungsform und methode zu ihrer herstellung
UY28622A1 (es) Agentes antibacterianos de quinolona
ES2053983T3 (es) Carboxamidas hetera-alifaticas.
ECSP045096A (es) Derivados de heteroarilo como ligandos superiores para el receptor de nociceptina orl-1"
ECSP067111A (es) Derivados de pirido-pirimidina, su preparación, su aplicación en terapéutica
NO20050612L (no) Pyrrolidinderivater som oksytocinantagonister
DOP2002000443A (es) Proceso para produccion de quinazolinas
PE20040658A1 (es) Derivados de 3-guanidinocarbonil-1-heteroaril-pirrol, procedimiento de preparacion e intermediarios de este procedimiento y composiciones farmaceuticas que los comprenden
AR021968A1 (es) Oximas e hidrazonas sustituidas como antagonistas de neuroquinina
AR033779A1 (es) Compuestos utiles en la enfermedad de reflujo

Legal Events

Date Code Title Description
FB Suspension of granting procedure